Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ScinoPharm Taiwan, Ltd. (1789.TW)
Tainan City, TW
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients throughout Taiwan, the United States, Europe, India, various parts of Asia, and other international regions. Its service offerings include custom synthesis for biochemical molecules like peptides and nucleic acids, manufacturing of generic APIs, and comprehensive outsourcing solutions. ScinoPharm also provides Contract Research and Manufacturing (CRAM) services, which involve chemistry expertise, analytical and regulatory support, chemical process development, clinical drug substance manufacturing, and consulting. These CRAM services facilitate the creation and production of APIs and intermediates for clinical, small-scale, and commercial applications. Moreover, the company actively develops advanced peptide synthesis technologies. ScinoPharm is involved in the development and manufacturing of a diverse range of products, such as Western medicines, various chemical materials, albumin-based drugs, oligonucleotide medicines, injectables, and novel small molecule drugs, alongside offering biotechnology and technical services. The company holds a strategic alliance with Baxter International Inc. focused on the joint development, production, and commercialization of an antiemetic drug for cancer chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and has its headquarters in Tainan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.32% | -5.17% | -8.98% | -12.10% | +9.07% | +14.93% | +0.79% | -25.68% | -27.08% | -49.58% | -47.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.1% Q1'26: -3.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-60.5% Q1'26: -66.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.8% Q1'26: +39.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.0% Q1'26: +1.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.8% Q1'26: +0.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.6% Q1'26: +7.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.13× ★ Q1'26: 22.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.96B
est: 4.01B (-1.3%)
|
4.03B
est: 4.12B (-2.1%)
|
3.52B
est: 3.56B (-1.1%)
|
3.52B
est: 3.64B (-3.1%)
|
2.89B
est: 3.34B (-13.3%)
|
3.08B
est: 3.13B (-1.4%)
|
2.76B
est: 2.96B (-6.5%)
|
3.26B
est: 3.06B (+6.8%)
|
3.19B
est: 3.09B (+3.3%)
|
3.41B
est: 3.03B (+12.3%)
|
3.16B
est: 3.23B (-2.0%)
|
3.83B
3.83B – 3.83B
+18.7% YoY
|
| EBITDA |
1.29B
est: 1.04B (+24.8%)
|
1.29B
est: 1.07B (+21.2%)
|
984.47M
est: 920.50M (+7.0%)
|
964.23M
est: 941.24M (+2.4%)
|
729.46M
est: 863.47M (-15.5%)
|
766.87M
est: 808.91M (-5.2%)
|
690.37M
est: 764.87M (-9.7%)
|
885.34M
est: 791.01M (+11.9%)
|
819.15M
est: 798.39M (+2.6%)
|
909.38M
est: 763.03M (+19.2%)
|
673.97M
est: 812.35M (-17.0%)
|
964.35M
964.35M – 964.35M
+18.7% YoY
|
| EBIT |
811.90M
est: 485.21M (+67.3%)
|
846.72M
est: 498.52M (+69.8%)
|
551.93M
est: 430.80M (+28.1%)
|
558.41M
est: 440.51M (+26.8%)
|
320.74M
est: 404.11M (-20.6%)
|
373.67M
est: 378.58M (-1.3%)
|
308.83M
est: 357.97M (-13.7%)
|
445.87M
est: 370.20M (+20.4%)
|
357.99M
est: 373.65M (-4.2%)
|
421.10M
est: 323.87M (+30.0%)
|
157.24M
est: 344.81M (-54.4%)
|
409.33M
409.33M – 409.33M
+18.7% YoY
|
| Net Income |
634.97M
est: 660.65M (-3.9%)
|
658.69M
est: 736.65M (-10.6%)
|
422.37M
est: 502.71M (-16.0%)
|
442.98M
est: 569.61M (-22.2%)
|
216.66M
est: 330.37M (-34.4%)
|
282.07M
est: 453.02M (-37.7%)
|
243.47M
est: 363.13M (-33.0%)
|
353.22M
est: 356.79M (-1.0%)
|
287.06M
est: 248.43M (+15.5%)
|
339.35M
est: 265.85M (+27.6%)
|
136.95M
est: 249.73M (-45.2%)
|
370.57M
370.57M – 370.57M
+48.4% YoY
|
| SGA |
602.74M
est: 779.38M (-22.7%)
|
658.11M
est: 800.77M (-17.8%)
|
676.92M
est: 691.98M (-2.2%)
|
670.89M
est: 707.58M (-5.2%)
|
670.96M
est: 649.11M (+3.4%)
|
696.32M
est: 608.10M (+14.5%)
|
685.79M
est: 574.99M (+19.3%)
|
573.88M
est: 594.64M (-3.5%)
|
543.83M
est: 600.19M (-9.4%)
|
518.14M
est: 546.90M (-5.3%)
|
490.30M
est: 582.25M (-15.8%)
|
691.20M
691.20M – 691.20M
+18.7% YoY
|
| EPS |
0.81
est: 0.83 (-2.8%)
|
0.83
est: 0.93 (-10.7%)
|
0.53
est: 0.63 (-16.4%)
|
0.56
est: 0.72 (-22.1%)
|
0.27
est: 0.42 (-35.2%)
|
0.36
est: 0.57 (-37.0%)
|
0.31
est: 0.46 (-32.3%)
|
0.45
est: 0.45 (+0.0%)
|
0.36
est: 0.31 (+14.9%)
|
0.43
est: 0.33 (+30.3%)
|
0.17
est: 0.31 (-45.2%)
|
0.46
0.46 – 0.46
+48.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 19.4K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 111.9K | 0.65% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 15.5K | 0.56% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 517.4K | 0.06% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 55.5K | 0.46% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 179.6K | 0.39% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 15.3K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 34.6K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.71M | 0.06% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 117.1K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chih-Hui Lin | Senior Director of Accounting, Finance & Corporate Governance Officer | — | female |
| Jason Chen | Director of Human Resources & Admin | — | male |
| Li-An Lu | President & Chief Executive Officer | — | female |
| Li-Chiao Chang Chemistry | Vice President of R&D Division and Chief Scientific Officer | — | — |
| Ling-Hsiao Lien | Vice-President of Marketing, Sales & Operations | — | male |
| Shun Yang Lin | Director of Corporate Development | — | male |
| Yao-Hui Wang | Senior Manager-Division of Accounting | — | — |
| Zhi-Xian Luo | Chairman & General Chief Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1789.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
